1. A method of achieving no emesis during the overall phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more
than one hour prior to administration of moderately or highly emetogenic chemotherapy, comprising a therapeutically effective amount of a) netupitant and b) palonosetron, or pharmaceutically acceptable salts thereof, wherein no emesis is obtained, as
measured by no emetic episodes occurring within at least about 120 hours after the start of the moderately or highly emetogenic chemotherapy.

2. A method of achieving no emesis during the acute phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly emetogenic
chemotherapy, comprising a therapeutically effective amount of a) netupitant and b) palonosetron, or pharmaceutically acceptable salts thereof, wherein no emesis is obtained, as measured by no emetic episodes occurring within at least about 24 hours
after the start of the moderately or highly emetogenic chemotherapy.

3. A method of achieving no emesis during the delayed phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly emetogenic
chemotherapy, comprising a therapeutically effective amount of a) netupitant and b) palonosetron, or pharmaceutically acceptable salts thereof, wherein no emesis is obtained, as measured by no emetic episodes occurring within at least about 24 to 120
hours after the start of the moderately or highly emetogenic chemotherapy.

4. A method of achieving no significant nausea during the overall phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly
emetogenic chemotherapy, comprising a therapeutically effective amount of a) netupitant and b) palonosetron, or pharmaceutically acceptable salts thereof, wherein no significant nausea is obtained, as measured by a maximum VAS <25 mm within at least
about 120 hours after the start of the moderately or highly emetogenic chemotherapy.

5. A method of achieving no significant nausea during the acute phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly
emetogenic chemotherapy, comprising a therapeutically effective amount of a) netupitant and b) palonosetron, or pharmaceutically acceptable salts thereof, wherein no significant nausea is obtained, as measured by a maximum VAS <25 mm within at least
about 24 hours after the start of the moderately or highly emetogenic chemotherapy.

6. A method of achieving no significant nausea during the delayed phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly
emetogenic chemotherapy, comprising a therapeutically effective amount of a) netupitant and b) palonosetron, or pharmaceutically acceptable salts thereof, wherein no significant nausea is obtained, as measured by a maximum VAS <25 mm within at least
about 24 to 120 hours after the start of the moderately or highly emetogenic chemotherapy.

7. A method of achieving no nausea during the delayed phase in a human subject in need thereof comprising administering to said subject an oral dosage form, no more than one hour prior to administration of moderately or highly emetogenic
chemotherapy, comprising a therapeutically effective amount of a) netupitant and b) palonosetron, or pharmaceutically acceptable salts thereof, wherein no nausea is obtained, as measured by a maximum VAS <5 mm within at least about 24 to 120 hours
after the start of the moderately or highly emetogenic chemotherapy.

8. The method of claim 1, wherein the oral dosage form comprises about 300 mg netupitant and about 0.5 mg palonosetron hydrochloride based on the weight of the free base.

10. The method of claim 1, wherein when said chemotherapy is highly emetic chemotherapy, the chemotherapy is selected from the group consisting of carmustine, cisplatin, cyclophosphamide .gtoreq.1500 mg/m.sup.2, dacarbazine, dactinomycin,
mechlorethamine, streptozotocin and combinations thereof.

11. The method of claim 1, wherein when said chemotherapy is moderately emetic chemotherapy, the chemotherapy is selected from the group consisting of carboplatin, cyclophosphamide <1500 mg/m.sup.2, cytarabine >1 mg/m.sup.2, daunorubicin,
doxorubicin, epirubicin, idarubicin, ifosfamide, irinotecan, oxaliplatin and combinations thereof.

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.